CTIC Cell Therapeutics, Inc. featured news, full reports, and detailed charts
Cell Therapeutics, Inc. (CTIC) Wrap Up:
Cell Therapeutics, Inc. markets lymphoma drug, Zevalin, in the United States. Zevalin is an FDA-approved radioimmunotherapeutic for treating lymphoma. The company also develops, acquires, and commercializes novel treatments for cancer. In addition, Cell Therapeutics develops XYOTAX for the treatment of non-small cell lung cancer and ovarian cancer; Pixantrone, a novel compound in the class of drugs known as anthracyclines, for non-Hodgkin’s lymphoma; and Brostallicin, which is in first-line Phase II study for the treatment of sarcoma. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd. and PG-TXL Company, L.P. The company was founded in 1991 and i...www.cticseattle.com
194 Employees
Founded in 1991
Cell Therapeutics, Inc. (CTIC:NASDAQ)
LAST $1.08 USD
CHANGE TODAY -0.03 -2.70%
VOLUME 6.3M
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Cell Therapeutics, Inc. (CTIC)
|
OPEN
$1.07
|
PREVIOUS CLOSE
$1.11
|
|
|
DAY HIGH
$1.09
|
DAY LOW
$1.06
|
|
|
52 WEEK HIGH
06/1/09 - $2.23
|
52 WEEK LOW
02/23/09 - $0.05
|
|
|
MARKET CAP
620.4M
|
AVERAGE VOLUME 3 mo
8.1M
|
|
|
DILUTED EPS TTM
$-0.71
|
SHARES OUTSTANDING
574.4M
|
|
|
CTIC Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Judges: Seattle biotech can pursue $23M claim
AP Digital - 11/18/2009 8:08 PM ET
CTIC Top Compensated Officers
Dr. James A. Bianco M.D.
Principal Founder, Chief Executive Officer an...
Age: 52
Total Annual Compensation: $1.0M
Mr. Craig W. Philips
President
Age: 48
Total Annual Compensation: $189.8K
Mr. Louis A. Bianco CPA
Co-Founder, Principal Financial Officer, Prin...
Age: 56
Total Annual Compensation: $429.0K
Dr. Jack W. Singer M.D.
Founder, Chief Medical Officer, Executive Vic...
Age: 66
Total Annual Compensation: $425.0K
Mr. Dan Eramian
Executive Vice President of Corporate Communi...
Age: 61
Total Annual Compensation: $393.8K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Cell Therapeutics, Inc. (CTIC)
Cell Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
11/5/2009
Cell Therapeutics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. Net loss attributable to common shareholders was $48.8 million or $0.09 per basic and diluted share compared to a net loss attributable to common shareholders of $47.6 million or $2.83 per basic and diluted share for the same period in 2008. The net loss for the quarter ended September 30, 2009 included the following non-cash expenses: $11.4 million in equity-based compensation expense, $6.0 million in milestone payment modification expense and $13.8 million preferred stock deemed dividend expenses. The company reported loss from operations of $27.071 million on total revenues of $20,000 compared to loss from operations of $17.858 million on total revenues of $20.60 million for the same period of last year. Net loss attributable to shareholders decreased 45% to $89.4 million or $0.21 per basic and diluted share, compared to a net loss attributable to shareholders of $161.6 million or $13.68 per basic and diluted share for the same period in 2008. The company reported loss from operations of $55.337 million on total revenues of $60,000 compared to loss from operations of $68.605 million on total revenues of $8.884 million for the same period of last year.
Cell Therapeutics, Inc. expected to Report Fiscal Year 2009 Results on March 15, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
11/5/2009
Cell Therapeutics, Inc. expected to Report Fiscal Year 2009 Results on March 15, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
Cell Therapeutics, Inc., Q3 2009 Earnings Call, Nov--05-2009
11/2/2009
Cell Therapeutics, Inc., Q3 2009 Earnings Call, Nov-05-2009
CTIC Competitors
| Company | Last | Change |
| Acusphere Inc | $0.08 USD | -0.002 |
| Antigenics Inc | $0.90 USD | -0.0599 |
| Arrowhead Research Corp | $0.65 USD | -0.01 |
| Genta Inc | $0.17 USD | +0.001 |
| Vion Pharmaceuticals Inc | $0.61 USD | +0.03 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | CTIC | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 218.3x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 193.1x |
|
|
CTIC |
||
|
CTIC transactions
| Type Date |
Target |
|
Private Placement
August 19, 2009 |
-- |
More Recent News About Cell Therapeutics, Inc.
More news for CTIC
Oculus, Bianco and Cel-Sci Oh My!: BioBuzz
Stock quotes in this article: OCLS , CTIC , CVM , ...Click here to read the whole Article (external link)
Q3 2009 Cell Therapeutics, Inc. Earnings Release - Time Not Supplied
Earnings Announcements for Thursday, November 5CompanySymbolTimeConferenceCall21st Century HoldingTCHC2:00 pm ET3I INFRASTRUCTURE3IN.LBefore Market OpenAbiomed, Inc.ABMDBefore Market OpenListenABOVENET INCABVTAfter Market CloseListenAbraxis BioScience, Inc.ABIIBefore Market OpenListenAccelrys Inc.ACCLAfter Market CloseListenACI Worldwide, Inc.ACIWBefore Market OpenACTIONS SEMICONDUCTOR CO LTDACTSAfter Market CloseActive Biotech ABACTI.STTime Not SuppliedActivision Blizzard, Inc.ATVIAfter Market CloseAdecco SAAHEXF.PK01:00 am ETAinsworth Lumber Company Ltd.ANS.TOAfter Market CloseAir MethodsAIRMAfter Market CloseAker ASAAKERTime Not SuppliedALAMOS GOLD INCAGI.TOBefore Market OpenAlaska Communications Systems GroupALSKAfter Market CloseAlexandria Real Estate...Click here to read the whole Article (external link)
CELL THERAPEUTICS INC Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Cell Therapeutics Lavishes Free Stock on Execs: BioBuzz
#popupbox { position: relative; } #share_links_popup { top: 12px; *top: 62px; /*ie*/ left: -120px; } #share_links_popup { text-transform:none; font-family:sans-serif; font-weight:normal; text-align:left; border:1px solid #cdcdcd; width:125px !important; padding:3px; display:none; z-index:100; background-color:white; position:absolute; } .sharelink_icon { background-image:url(/css/images/article_tools_icons.gif); background-repeat:no-repeat; border:0px solid gray; height:16px !important; padding-left:24px; padding-right:24px; font-size:8pt; font-family:Trebuchet MS; text-decoration:none; letter-spacing:0.01em; display:block; margin-top:4px !important; margin-bottom:4px; color:#000; width:90px !important; } #share_close_box { margin-right:2px; margin-top:2px; background-position:0 -184px ; width:16px; height:11px; font-family:sans-serif; font-weight:bold; text-decoration:none; float:right; } #share_close_box a { text-decoration:none; color:#cc0000; } #share_close_box a:hover { color:red; } #share_links { margin-top:4px; margin-left:0px; } #share_header { width:100%; /*background-color:#dedede; */ font-family:sans-serif; font-size:9pt; padding:4px; } ...Click here to read the whole Article (external link)
CELL THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Item 7.01 Regulation FD Disclosure. On November 17 and 18, 2009, Cell Therapeutics, Inc. (the "Company") will be meeting with certain banks in Italy and presenting a corporate overview of the Company. A copy of a slide presentation that the Company will be using at these meetings is furnished as Exhibit 99.1 hereto. The information provided pursuant to this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing or other document filed by the Company pursuant to the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings or documents, except to the extent expressly set forth by specific reference in such a filing or document. The information furnished pursuant to this Item 7.01 shall instead be deemed "furnished." Certain Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this Current Report on Form 8-K include statements about future financial and operating results, and risks and uncertainties that could affect the Company's products under development. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. ...Click here to read the whole Article (external link)
Would you like to leave a comment about Cell Therapeutics, Inc. CTIC
Find out what social network information about Cell Therapeutics, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Cell Therapeutics, Inc. there is more great information available at Realpennies.com